Dr. Francisco Moreno is a Professor of Psychiatry at the University of Arizona College of Medicine. He serves in a variety of roles at our institution including as: Associate Vice President at the University of Arizona Health Science, leading the Office of Diversity and Inclusion; Senior Investigator and Engagement Lead with the NIH-Precision Medicine Initiative’s grant “All of Us Research Program”; Principal Investigator of the Arizona Health Career Opportunity Program from DHHS-Health Resources and Services Administration grant “Arizona HOPE” which works to support the competitiveness of a diverse pipeline of students for health professions in our state; Multiple Principal Investigator of an NIH-NHLBI grant to enhance the research skill and career advancement of early-career faculty from diverse backgrounds who seek to improve health equity.
He has been conducting research in biology and treatment of mood and anxiety disorders, geared to improve our understanding of the brain basis for mental illness and the underlying mechanism of action of antidepressants / antianxiety drugs, and treatment resistance. In collaboration with partners from the Departments of Psychiatry, Psychology, Medical Imaging, and the Clinical and Translational Science center, he is conducting cutting edge research in the use of psychedelic agents for the treatment of Obsessive-Compulsive Disorder, and exploring the sleep, brain imaging and electrophysiology biomarkers of treatment response.
Dr. Moreno through his research collaborations utilizes various research methodologies such as molecular, biochemical, electrophysiological and behavioral correlates of depression. Biology and treatment of mood and anxiety disorders are key areas of his research interest. His work is funded by grants from the National Institutes of Health, Private Foundations, and Collaborations with Industry. He has supervised and mentored a number of interdisciplinary students, psychiatry residents, research fellows and junior faculty. His clinical interest and expertise include treatment resistant mood and anxiety disorders, and serves often as a psychopharmacology consultant to government institutions, health insurances, and pharmaceutical/device industry.